Deutsche Bank AG Purchases New Shares in Tarsus Pharmaceuticals, Inc. $TARS

Key Points

• Deutsche Bank initiated a position in Tarsus Pharmaceuticals during the second quarter, buying 65,457 shares valued at approximately $4.12 million. Institutional investors collectively own 90.01% of the company.
• Tarsus shares opened at $71.45, with the stock down 1.9%; the company reported a quarterly loss of $0.43 per share, missing estimates, despite revenue of $173.91 million exceeding expectations.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $90.50, although insiders sold 39,850 shares worth about $2.45 million over the past three months.

Deutsche Bank AG purchased a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 65,457 shares of the company's stock, valued at approximately $4,120,000. Deutsche Bank AG owned about 0.15% of Tarsus Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in TARS. Rockefeller Capital Management L.P. increased its stake in Tarsus Pharmaceuticals by 15.5% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company's stock valued at $105,000 after buying an additional 172 shares during the last quarter. Parallel Advisors LLC boosted its stake in shares of Tarsus Pharmaceuticals by 139.2% in the 1st quarter. Parallel Advisors LLC now owns 500 shares of the company's stock worth $35,000 after buying an additional 291 shares during the last quarter. State of Wisconsin Investment Board grew its holdings in shares of Tarsus Pharmaceuticals by 1.1% in the fourth quarter. State of Wisconsin Investment Board now owns 31,912 shares of the company's stock valued at $2,613,000 after acquiring an additional 332 shares in the last quarter. Federated Hermes Inc. grew its holdings in shares of Tarsus Pharmaceuticals by 0.6% in the second quarter. Federated Hermes Inc. now owns 55,021 shares of the company's stock valued at $2,229,000 after acquiring an additional 339 shares in the last quarter. Finally, Valeo Financial Advisors LLC increased its position in shares of Tarsus Pharmaceuticals by 11.1% during the fourth quarter. Valeo Financial Advisors LLC now owns 3,915 shares of the company's stock valued at $321,000 after acquiring an additional 392 shares during the last quarter. 90.01% of the stock is owned by institutional investors.

Insider Buying and Selling at Tarsus Pharmaceuticals

In related news, Director William J. Phd Link sold 12,500 shares of the company's stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $62.12, for a total transaction of $776,500.00. Following the sale, the director directly owned 106,786 shares in the company, valued at approximately $6,633,546.32. This represents a 10.48% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Katherine Goodrich sold 2,954 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $62.08, for a total transaction of $183,384.32. Following the completion of the transaction, the director owned 2,233 shares of the company's stock, valued at $138,624.64. This represents a 56.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 39,850 shares of company stock worth $2,452,821 over the last three months. Company insiders own 9.64% of the company's stock.

Tarsus Pharmaceuticals Stock Down 1.9%

TARS stock opened at $71.45 on Wednesday. The stock has a fifty day moving average of $63.88 and a 200-day moving average of $65.18. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $48.20 and a fifty-two week high of $85.25. The company has a market capitalization of $3.14 billion, a price-to-earnings ratio of -65.55 and a beta of 0.53. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.17 and a current ratio of 3.20.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.24). The firm had revenue of $173.91 million during the quarter, compared to the consensus estimate of $169.65 million. Tarsus Pharmaceuticals had a negative net margin of 7.67% and a negative return on equity of 13.53%. As a group, equities research analysts predict that Tarsus Pharmaceuticals, Inc. will post -2.06 earnings per share for the current year.

Analysts Set New Price Targets

TARS has been the topic of a number of recent analyst reports. Guggenheim dropped their price target on Tarsus Pharmaceuticals from $90.00 to $89.00 and set a "buy" rating on the stock in a report on Tuesday, July 21st. Wall Street Zen lowered Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Sunday, July 12th. Mizuho lowered their target price on Tarsus Pharmaceuticals from $100.00 to $98.00 and set an "outperform" rating on the stock in a research note on Friday, July 31st. Weiss Ratings reiterated a "sell (d-)" rating on shares of Tarsus Pharmaceuticals in a research note on Friday, July 17th. Finally, HC Wainwright reissued a "buy" rating and issued a $88.00 price target on shares of Tarsus Pharmaceuticals in a report on Thursday, July 9th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Tarsus Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $90.50.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company's research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus's lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.

Want to see what other hedge funds are holding TARS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source